Clinical trials: NASH
Type2 Diabetes, Fatty Liver, Nonalcoholic
Mechanism of Serum PRL in the Development of MAFLD
Metabolic associated fatty liver disease (MAFLD) has currently reached a worldwide epidemic. Serum PRL levels within or outside physiological range have been found to affect metabolic homeostasis differently.
- Conditions
- Type2 Diabetes, Fatty Liver, Nonalcoholic, Liver Fibrosis
- Trial name
- NCT05525884
- Testing
- non-invasive method, Fibroscan
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Shen Qu
Non Alcoholic Steatohepatitis
Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis
The purpose of the study is to see if the drug ezetimibe is a potential treatment for Nonalcoholic Steatohepatitis(NASH).
- Trial name
- NCT01766713
- Testing
- Ezetimibe
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
NAFLD - Nonalcoholic Fatty Liver Disease
Hepatic and Cardiac Metabolic Flexibility in Obese With NAFLD.
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum from reversible hepatic steatosis to inflammation and fibrosis termed steatohepatitis (NASH) and cirrhosis.
- Trial name
- NCT03583437
- Testing
- Exercise
- Where
- Denmark
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Diabetes type2, NASH - Nonalcoholic Steatohepatitis
NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL)
Non-alcoholic fatty liver diseases (NAFLD) include several entities ranging from simple steatosis to hepatic fibrosis or cirrhosis.
- Conditions
- Diabetes type2, NASH - Nonalcoholic Steatohepatitis, NAFLD
- Trial name
- NADRANK-1 (NCT03968354)
- Testing
- "Collection of additional blood tubes; Biobanking (plasma, liver tissue).
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Overweight and Obesity, NAFLD
Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects
The primary objective of this study is to evaluate the safety, tolerability and compare the pharmacokinetic parameters of ASC41, a THR beta agonist tables in overweight and obese subjects who have elevated LDL-C .
- Conditions
- Overweight and Obesity, NAFLD, Hyperlipidemia
- Trial name
- NCT04686994
- Testing
- ASC 41
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
Type 2 Diabetes, Prediabetes
Seum Bile Acid Profile in Type 2 Diabetes and Association Between Bile Cid Profile and Adipokine or Oxidative Stress
"The goal of this work is to critically test the hypothesis that there exists a different profile of bile acids (BAs) in patient with type 2 diabetes mellitus (T2DM) compared with normal controls.
- Conditions
- Type 2 Diabetes, Prediabetes, Non-alcoholic Fatty Liver Disease, Metabolic Syndrome
- Trial name
- NCT02650830
- Where
- South Korea
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Obesity, Morbid, Metabolic Syndrome
Biometabolic Outcomes After Weight Loss Surgery: An Individualized Approach
Variable outcomes after weight loss surgery are likely attributable to complex, poorly understood mechanisms. Due to the significant impact that morbid obesity has on a patient's health, successful management of obesity and its…
- Conditions
- Obesity, Morbid, Metabolic Syndrome, NASH - Nonalcoholic Steatohepatitis
- Trial name
- NCT04841057
- Testing
- 50 cm BP limb length, 100 cm BP limb length, 150 cm BP limb length
- Where
- United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Non-Alcoholic Fatty Liver Disease, Obesity
Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot Study
Non alcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver function tests in the U.S. (Browning, et al., 2004), ranging from steatosis to end-stage liver disease.
- Trial name
- NCT03339245
- Testing
- Fructose Solution (75 Grams), Glucose Solution (75 grams)
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Nonalcoholic Steatohepatitis (NASH)
Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics
This study will evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single- and multiple-oral doses of ZSP1601 on fasted condition, and characterize PK of ZSP1601 on an empty stomach (fasted condition) and…
- Trial name
- NCT03392779
- Testing
- ZSP1601 25 mg, ZSP1601 50 mg, ZSP1601 100 mg
- Where
- China
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Nonalcoholic Fatty Liver Disease
Elucidating Growth Hormone Dynamics at Stages of Progressive Nonalcoholic Fatty Liver Disease
The purpose of this study is to investigate relationships between the body's growth hormone "axis" and nonalcoholic fatty liver disease.
- Trial name
- NCT06166797
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Non-alcoholic Fatty Liver Disease
Effect of Supplementation of Fish Oil on Non-alcoholic Fatty Liver Disease in Children
The aim of this study is to evaluate efficacy of fish oil (EPA/DHA) in children with non-alcoholic fatty liver disease.
- Trial name
- NCT01547910
- Testing
- Fish Oil
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Piotr Socha
Atherosclerosis, Cardiovascular Risk Factor
Early Vascular Ageing in the YOUth
This is a single-center observational study on adolescents to determine predictors of the early steps of the formation of atherosclerosis and to quantify their influence on Intima-Media-Thickness of the carotid artery and the…
- Conditions
- Atherosclerosis, Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Pathology
- Trial name
- EVA4YOU (NCT04598685)
- Where
- Austria
- Volunteers
- 1,517 people, healthy volunteers welcome
- Sponsor
- VASCage GmbH
Healthy
A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese Adults
The current study is designed to evaluate the safety, tolerability and pharmacokinetics of PF-05221304 in healthy Japanese adult subjects following single and multiple dose administration.
- Trial name
- NCT03597217
- Testing
- PF-05221304
- Where
- Japan
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Pfizer
Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH)
Longitudinal Observational Study Of Chinese With NAFLD/NASH
This is a 10-year, longitudinal, observational study of patients with NAFLD/NASH designed to specifically address important clinical questions that remain incompletely answered from registration trials.
- Trial name
- NCT03151473
- Where
- Hong Kong
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Humanity and Health Research Centre
Obese
Changes in Intrahepatic Lipids With Exercise
Individuals with obesity and particular type 2 diabetes have abnormally high levels of fat in liver cells and are at increased risk for cardiovascular and liver-related mortality.
- Trial name
- NCT02181270
- Testing
- high intensity exercise, continuous moderate exercise
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
NASH
A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar
non-alcoholic steatohepatitis (NASH) is an inflammatory liver disease caused by the accumulation of fat in liver cells. With the change of living habits and diet, the incidence of Nash continues to increase.
- Trial name
- NCT06193629
- Testing
- Lang Qingata
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Shupei Li
Type2 Diabetes Mellitus, Microangiopathy
"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population
Current methods based on traditional Cardiovascular risk factors are not clinically useful for identifying Type 2 Diabetes patients at risk of developing acute Cardiovascular ischemic events (ie.myocardial infarction or stroke).
- Conditions
- Type2 Diabetes Mellitus, Microangiopathy, Non Alcoholic Fatty Liver Disease, Coronary Artery Disease
- Trial name
- PRECISED (NCT02248311)
- Where
- Spain
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Non-alcoholic Fatty Liver Disease (NAFLD)
Exercise Dose and Nonalcoholic Fatty Liver Disease
The purpose of this research is to provide a better understanding of how exercise (walking) affects non-alcoholic fatty liver disease (NAFLD) in overweight people.
- Trial name
- ED (NCT00771108)
- Testing
- exercise
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Healthy
Study of Multiple Oral Doses of PF-06835919 in Healthy Adult Japanese Participants
This is a Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of multiple oral doses of PF-06835919 in healthy adult Japanese participants.
- Trial name
- NCT04427917
- Testing
- PF-06835919
- Where
- Belgium
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pfizer
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Conditionally Increased Output (CIO) Enhanced Ultrasound System
This study aims to assess possible bioeffects that may be caused by the use of shear wave elastography (SWE) with conditionally increased acoustic output pressure (CIO).
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fatty Liver
- Trial name
- NCT05792423
- Testing
- GE ultrasound system with increased acoustic output settings
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital